# Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

> **NCT05245071** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 22 (actual)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Tusamitamab ravtansine

## Key facts

- **NCT ID:** NCT05245071
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-01
- **Primary completion:** 2024-03-06
- **Final completion:** 2024-11-20
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Sponsor decision, the decision is not related to any safety concern.
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245071, "Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05245071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*